RLY-2608 + Capivasertib + Fulvestrant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA Mutation
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Trial Timeline
Aug 26, 2025 → Dec 31, 2031
NCT ID
NCT06982521About RLY-2608 + Capivasertib + Fulvestrant
RLY-2608 + Capivasertib + Fulvestrant is a phase 3 stage product being developed by Relay Therapeutics for PIK3CA Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06982521. Target conditions include PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06982521 | Phase 3 | Recruiting |
Competing Products
13 competing products in PIK3CA Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| alpelisib | Novartis | Pre-clinical | 23 |
| BYL719 + Fulvestrant | Novartis | Phase 1 | 33 |
| BYL719 + AMG 479 | Novartis | Phase 1/2 | 41 |
| Inavolisib + Atezolizumab + Pembrolizumab | Roche | Phase 1 | 33 |
| CGT6297 | Cogent Biosciences | Phase 1 | 30 |
| RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | Relay Therapeutics | Phase 1 | 28 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 47 |
| RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg | Relay Therapeutics | Phase 1 | 28 |